-$0.25 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter

Equities research analysts expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to post earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.17). Sunesis Pharmaceuticals reported earnings per share of ($0.44) in the same quarter last year, which suggests a positive year over year growth rate of 43.2%. The firm is expected to announce its next earnings results on Thursday, March 8th.

On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.58) per share for the current financial year, with EPS estimates ranging from ($1.66) to ($1.48). For the next year, analysts expect that the firm will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same quarter in the previous year, the firm posted ($0.62) earnings per share.

Several equities analysts have issued reports on SNSS shares. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Thursday, August 24th. ValuEngine downgraded Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Cantor Fitzgerald reissued a “hold” rating and issued a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Wednesday, September 27th. Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. Finally, UBS started coverage on Sunesis Pharmaceuticals in a report on Monday, November 20th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Sunesis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $3.75.

Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up $0.96 on Friday, reaching $3.44. The company’s stock had a trading volume of 2,390,408 shares, compared to its average volume of 131,449. Sunesis Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $4.45. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84.

In other Sunesis Pharmaceuticals news, major shareholder Mpm Oncology Impact Management acquired 81,500 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was acquired at an average cost of $2.77 per share, for a total transaction of $225,755.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dayton Misfeldt acquired 400,000 shares of the business’s stock in a transaction dated Friday, October 27th. The stock was acquired at an average price of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. Insiders acquired 506,800 shares of company stock valued at $1,091,282 over the last three months. 10.21% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of SNSS. Balyasny Asset Management LLC acquired a new position in Sunesis Pharmaceuticals during the second quarter worth $5,400,000. Virtu KCG Holdings LLC acquired a new position in Sunesis Pharmaceuticals during the second quarter worth $208,000. Sphera Funds Management LTD. boosted its stake in Sunesis Pharmaceuticals by 54.6% during the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 68,212 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Sunesis Pharmaceuticals by 127.6% during the third quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 53,396 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Sunesis Pharmaceuticals by 4.1% during the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after buying an additional 23,819 shares during the last quarter. Hedge funds and other institutional investors own 38.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://weekherald.com/2017/12/11/0-25-earnings-per-share-expected-for-sunesis-pharmaceuticals-inc-snss-this-quarter.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply